• Introduce the rationale for targeting ROPN1 as a novel and tumour-specific antigen in TNBC
• Highlight how next-generation TCR engineering enhances specificity and potency against hard-to-treat solid tumours
• Discuss translational and clinical development plans to demonstrate safety, efficacy, and durable responses in TNBC patients

New Data